Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions

Bone

Volumn 48, Issue 1, 2011, Pages 54-65

  Schneider, Jochen G ^b,c   Amend, Sarah R ^a   Weilbaecher, Katherine N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

Bone metastasis; Cancer therapy; Endothelium; Integrins; Osteoclasts; Platelets

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ANTIMETASTATIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BETA1 INTEGRIN; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; DENOSUMAB; EMD 1219974; ETARACIZUMAB; GLPG 0187; INTEGRIN; INTETUMUMAB; L 000845704; MONOCLONAL ANTIBODY; OSTEOPONTIN; PLERIXAFOR; S 247; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID;

BONE DESTRUCTION; BONE MARROW CELL; BONE METASTASIS; BONE PAIN; CANCER INVASION; CELL HOMING; CELL INTERACTION; CLINICAL TRIAL; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; LUNG CANCER; MEGAKARYOCYTE; MYELOMA; NONHUMAN; OSTEOCLAST; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEM CELL MOBILIZATION; STROMA CELL; THROMBOCYTE AGGREGATION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

BONE AND BONES; BONE NEOPLASMS; CELL COMMUNICATION; EXTRACELLULAR MATRIX; FORECASTING; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHAVBETA3; INTEGRINS; NEOPLASMS; OSTEOCLASTS; OSTEOPONTIN; STROMAL CELLS;

EID: 78650304364     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.09.016     Document Type: Review

References (284)

1. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004, 2:205-213. [discussion 213-4, 216-7, 219-20].
2. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
3. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
4. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
5. Lipton A., Costa L., Ali S., Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001, 28:54-59.
6. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
7. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
8. Hirbe A., Morgan E.A., Uluckan O., Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006, 12:6309s-6314s.
9. Hirbe A.C., Rubin J., Uluckan O., Morgan E.A., Eagleton M.C., Prior J.L., et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A 2007, 104:14062-14067.
10. Bendre M.S., Montague D.C., Peery T., Akel N.S., Gaddy D., Suva L.J. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003, 33:28-37.
11. Pfeilschifter J., D'Souza S.M., Mundy G.R. Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology 1987, 121:212-218.
12. Kozlow W., Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005, 10:169-180.
13. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol Cancer Ther 2007, 6:2609-2617.
14. Clines G.A., Guise T.A. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
15. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
16. Kakonen S.M., Selander K.S., Chirgwin J.M., Yin J.J., Burns S., Rankin W.A., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002, 277:24571-24578.
17. Hamdy N.A. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc) 2008, 44:7-21.
18. Body J.J., Lipton A., Gralow J., Steger G.G., Gao G., Yeh H., et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 2009.
19. Fizazi K., Lipton A., Mariette X., Body J.J., Rahim Y., Gralow J.R., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
20. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995, 11:549-599.
21. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
22. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
23. Shattil S.J., Kim C., Ginsberg M.H. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010, 11:288-300.
24. Qin J., Vinogradova O., Plow E.F. Integrin bidirectional signaling: a molecular view. PLoS Biol 2004, 2:e169.
25. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006, 99:1293-1304.
26. Ma Y.Q., Qin J., Wu C., Plow E.F. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol 2008, 181:439-446.
27. Tadokoro S., Shattil S.J., Eto K., Tai V., Liddington R.C., de Pereda J.M., et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003, 302:103-106.
28. Vinogradova O., Velyvis A., Velyviene A., Hu B., Haas T., Plow E., et al. A structural mechanism of integrin alpha(IIb)beta(3) "inside-out" activation as regulated by its cytoplasmic face. Cell 2002, 110:587-597.
29. Harburger D.S., Calderwood D.A. Integrin signalling at a glance. J Cell Sci 2009, 122:159-163.
30. Montanez E., Ussar S., Schifferer M., Bosl M., Zent R., Moser M., et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 2008, 22:1325-1330.
31. Moser M., Nieswandt B., Ussar S., Pozgajova M., Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008, 14:325-330.
32. Lai-Cheong J.E., Parsons M., McGrath J.A. The role of kindlins in cell biology and relevance to human disease. Int J Biochem Cell Biol 2010, 42:595-603.
33. Kamae T., Shiraga M., Kashiwagi H., Kato H., Tadokoro S., Kurata Y., et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation. J Thromb Haemost 2006, 4:1379-1387.
34. Woulfe D., Jiang H., Mortensen R., Yang J., Brass L.F. Activation of Rap1B by G(i) family members in platelets. J Biol Chem 2002, 277:23382-23390.
35. Chen Y.P., O'Toole T.E., Ylanne J., Rosa J.P., Ginsberg M.H. A point mutation in the integrin beta 3 cytoplasmic domain (S752-->P) impairs bidirectional signaling through alpha IIb beta 3 (platelet glycoprotein IIb-IIIa). Blood 1994, 84:1857-1865.
36. Hughes P.E., Diaz-Gonzalez F., Leong L., Wu C., McDonald J.A., Shattil S.J., et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem 1996, 271:6571-6574.
37. O'Toole T.E., Katagiri Y., Faull R.J., Peter K., Tamura R., Quaranta V., et al. Integrin cytoplasmic domains mediate inside-out signal transduction. J Cell Biol 1994, 124:1047-1059.
38. Vinogradova O., Haas T., Plow E.F., Qin J. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci U S A 2000, 97:1450-1455.
39. Vinogradova O., Vaynberg J., Kong X., Haas T.A., Plow E.F., Qin J. Membrane-mediated structural transitions at the cytoplasmic face during integrin activation. Proc Natl Acad Sci U S A 2004, 101:4094-4099.
40. Ylanne J., Huuskonen J., O'Toole T.E., Ginsberg M.H., Virtanen I., Gahmberg C.G. Mutation of the cytoplasmic domain of the integrin beta 3 subunit. Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis. J Biol Chem 1995, 270:9550-9557.
41. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010: 9-22. [Review].
42. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001, 11:130-135.
43. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13:555-562.
44. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
45. Frisch S.M., Vuori K., Ruoslahti E., Chan-Hui P.Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996, 134:793-799.
46. Demers M.J., Thibodeau S., Noel D., Fujita N., Tsuruo T., Gauthier R., et al. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. J Cell Biochem 2009, 107:639-654.
47. Shain K.H., Landowski T.H., Dalton W.S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002, 168:2544-2553.
48. Simpson K.J., Selfors L.M., Bui J., Reynolds A., Leake D., Khvorova A., et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol 2008, 10:1027-1038.
49. Edlund M., Miyamoto T., Sikes R.A., Ogle R., Laurie G.W., Farach-Carson M.C., et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001, 12:99-107.
50. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000, 5:75-81.
51. Clezardin P. Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 2009, 9:801-806.
52. van der P., Vloedgraven H., Papapoulos S., Lowick C., Grzesik W., Kerr J., et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997, 77:665-675.
53. Liapis H., Flath A., Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996, 5:127-135.
54. McCabe N.P., De S., Vasanji A., Brainard J., Byzova T.V. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007, 26:6238-6243.
55. Townsend P.A., Villanova I., Uhlmann E., Peyman A., Knolle J., Baron R., et al. An antisense oligonucleotide targeting the alphaV integrin gene inhibits adhesion and induces apoptosis in breast cancer cells. Eur J Cancer 2000, 36:397-409.
56. Gillespie M.T., Thomas R.J., Pu Z.Y., Zhou H., Martin T.J., Findlay D.M. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997, 73:812-815.
57. Van der Velde-Zimmermann D., Verdaasdonk M.A., Rademakers L.H., De Weger R.A., Van den Tweel J.G., Joling P. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 1997, 230:111-120.
58. Takayama S., Ishii S., Ikeda T., Masamura S., Doi M., Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 2005, 25:79-83.
59. Nakamura I., Duong le T., Rodan S.B., Rodan G.A. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 2007, 25:337-344.
60. Pecheur I., Peyruchaud O., Serre C.M., Guglielmi J., Voland C., Bourre F., et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002, 16:1266-1268.
61. Sloan E.K., Pouliot N., Stanley K.L., Chia J., Moseley J.M., Hards D.K., et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006, 8:R20.
62. Zhao Y., Bachelier R., Treilleux I., Pujuguet P., Peyruchaud O., Baron R., et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007, 67:5821-5830.
63. Martin-Thouvenin V., Gendron M.C., Hogervorst F., Figdor C.G., Lanotte M. Phorbol ester-induced promyelocytic leukemia cell adhesion to marrow stromal cells involves fibronectin specific alpha 5 beta 1 integrin receptors. J Cell Physiol 1992, 153:95-102.
64. Korah R., Boots M., Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004, 64:4514-4522.
65. Liesveld J.L., Dipersio J.F., Abboud C.N. Integrins and adhesive receptors in normal and leukemic CD34+ progenitor cells: potential regulatory checkpoints for cellular traffic. Leuk Lymphoma 1994, 14:19-28.
66. Lang S.H., Clarke N.W., George N.J., Testa N.G. Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis 1997, 15:218-227.
67. Hall C.L., Dai J., van Golen K.L., Keller E.T., Long M.W. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006, 66:8648-8654.
68. Hall C.L., Dubyk C.W., Riesenberger T.A., Shein D., Keller E.T., van Golen K.L. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008, 10:797-803.
69. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P.J., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004, 104:2149-2154.
70. Michigami T., Shimizu N., Williams P.J., Niewolna M., Dallas S.L., Mundy G.R., et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96:1953-1960.
71. Matsuura N., Puzon-McLaughlin W., Irie A., Morikawa Y., Kakudo K., Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol 1996, 148:55-61.
72. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638-649.
73. Ross F.P., Teitelbaum S.L. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005, 208:88-105.
74. Novack D.V., Teitelbaum S.L. The osteoclast: friend or foe?. Annu Rev Pathol 2008, 3:457-484.
75. Ross F.P., Chappel J., Alvarez J.I., Sander D., Butler W.T., Farach-Carson M.C., et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993, 268:9901-9907.
76. McHugh K.P. Mice lacking b3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105:433-440.
77. Bakewell S.J., Nestor P., Prasad S., Tomasson M.H., Dowland N., Mehrotra M., et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 2003, 100:14205-14210.
78. Zambonin Zallone A., Teti A., Gaboli M., Marchisio P.C. Beta 3 subunit of vitronectin receptor is present in osteoclast adhesion structures and not in other monocyte-macrophage derived cells. Connect Tissue Res 1989, 20:143-149.
79. Crippes B.A., Engleman V.W., Settle S.L., Delarco J., Ornberg R.L., Helfrich M.H., et al. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology 1996, 137:918-924.
80. Chellaiah M.A. Regulation of podosomes by integrin alphavbeta3 and Rho GTPase-facilitated phosphoinositide signaling. Eur J Cell Biol 2006, 85:311-317.
81. Faccio R., Takeshita S., Zallone A., Ross F.P., Teitelbaum S.L. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 2003, 111:749-758.
82. Faccio R., Grano M., Colucci S., Zallone A.Z., Quaranta V., Pelletier A.J. Activation of alphav beta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun 1998, 249:522-525.
83. Miyauchi A., Alvarez J., Greenfield E.M., Teti A., Grano M., Colucci S., et al. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991, 266:20369-20374.
84. Rucci N., DiGiacinto C., Orru L., Millimaggi D., Baron R., Teti A. A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells. J Cell Sci 2005, 118:3263-3275.
85. Zhang Z., Baron R., Horne W.C. Integrin engagement, the actin cytoskeleton, and c-Src are required for the calcitonin-induced tyrosine phosphorylation of paxillin and HEF1, but not for calcitonin-induced Erk1/2 phosphorylation. J Biol Chem 2000, 275:37219-37223.
86. Clohisy D.R., Ramnaraine M.L. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 1998, 16:660-666.
87. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521-528.
88. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heinegard D., Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003, 20:437-444.
89. Heinegard D., Andersson G., Reinholt F.P. Roles of osteopontin in bone remodeling. Ann N Y Acad Sci 1995, 760:213-222.
90. Katayama Y., House C.M., Udagawa N., Kazama J.J., McFarland R.J., Martin T.J., et al. Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. J Cell Physiol 1998, 176:179-187.
91. Hayashi C., Rittling S., Hayata T., Amagasa T., Denhardt D., Ezura Y., et al. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 2007, 101:979-986.
92. Denhardt D.T., Chambers A.F. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994, 56:48-51.
93. Nemoto H., Rittling S.R., Yoshitake H., Furuya K., Amagasa T., Tsuji K., et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001, 16:652-659.
94. Ohyama Y., Nemoto H., Rittling S., Tsuji K., Amagasa T., Denhardt D.T., et al. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res 2004, 19:1706-1711.
95. Desai B., Rogers M.J., Chellaiah M.A. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007, 6:18.
96. Hullinger T.G., Taichman R.S., Linseman D.A., Somerman M.J. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem 2000, 78:607-616.
97. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
98. Standal T., Borset M., Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004, 26:179-184.
99. Chen Y.J., Wei Y.Y., Chen H.T., Fong Y.C., Hsu C.J., Tsai C.H., et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2009, 221:98-108.
100. Lundberg P., Koskinen C., Baldock P.A., Lothgren H., Stenberg A., Lerner U.H., et al. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction. Biochem Biophys Res Commun 2007, 352:444-448.
101. Uluckan O., Becker S.N., Deng H., Zou W., Prior J.L., Piwnica-Worms D., et al. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009, 69:3196-3204.
102. Han X., Sterling H., Chen Y., Saginario C., Brown E.J., Frazier W.A., et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 2000, 275:37984-37992.
103. Rachkovsky M., Sodi S., Chakraborty A., Avissar Y., Bolognia J., McNiff J.M., et al. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis 1998, 16:299-312.
104. Vignery A. Macrophage fusion: are somatic and cancer cells possible partners?. Trends Cell Biol 2005, 15:188-193.
105. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
106. Stupack D.G., Cheresh D.A. Integrins and angiogenesis. Curr Top Dev Biol 2004, 64:207-238.
107. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2:91-100.
108. Hodivala-Dilke K. alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 2008, 20:514-519.
109. Silva R., D'Amico G., Hodivala-Dilke K.M., Reynolds L.E. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 2008, 28:1703-1713.
110. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
111. Morga E.A., Schneider J., Uluckan T.B., Heller E.A., Hurchla M.A., et al. Dissection of platelet and myeloid cell defects by conditional targeting of the β3 integrin subunit. FASEB J 2010, 24:1117-1127.
112. Cackowski F.C., Anderson J.L., Patrene K.D., Choksi R.J., Shapiro S.D., Windle J.J., et al. Osteoclasts are important for bone angiogenesis. Blood 2010, 115:140-149.
113. Capoccia B.J., Shepherd R.M., Link D.C. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 2006, 108:2438-2445.
114. De Palma M., Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006, 1766:159-166.
115. Papaspyridonos M., Lyden D. Chapter 11. The role of bone marrow-derived cells in tumor angiogenesis and metastatic progression. Methods Enzymol 2008, 444:255-269.
116. Ramjaun A.R., Hodivala-Dilke K. The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol 2009, 41:521-530.
117. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
118. Mahabeleshwar G.H., Byzova T.V. Vascular integrin signaling. Methods Enzymol 2008, 443:199-226.
119. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
120. Brooks P.C., Silletti S., von Schalscha T.L., Friedlander M., Cheresh D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92:391-400.
121. Silletti S., Kessler T., Goldberg J., Boger D.L., Cheresh D.A. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A 2001, 98:119-124.
122. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 2001, 276:31959-31968.
123. Nemeth J.A., Cher M.L., Zhou Z., Mullins C., Bhagat S., Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20:413-420.
124. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8:27-34.
125. Reynolds A.R., Reynolds L.E., Nagel T.E., Lively J.C., Robinson S.D., Hicklin D.J., et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 2004, 64:8643-8650.
126. Carmeliet P. Integrin indecision. Nat Med 2002, 8:14-16.
127. Martin K.H., Slack J.K., Boerner S.A., Martin C.C., Parsons J.T. Integrin connections map: to infinity and beyond. Science 2002, 296:1652-1653.
128. Wang X.Q., Sun P., Paller A.S. Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J Biol Chem 2001, 276:44504-44511.
129. Zhao H., Ross F.P., Teitelbaum S.L. Unoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol 2005, 19:771-780.
130. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009, 15:392-400.
131. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502.
132. Bellahcene A., Chaplet M., Bonjean K., Castronovo V. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium 2007, 14:123-130.
133. Hirbe A.C., Roelofs A.J., Floyd D.H., Deng H., Becker S.N., Lanigan L.G., et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44:908-916.
134. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
135. Gao L., Deng H., Zhao H., Hirbe A., Harding J., Ratner L., et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005, 106:4294-4302.
136. Coleman R.E., Guise T.A., Lipton A., Roodman G.D., Berenson J.R., Body J.J., et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008, 14:6387-6395.
137. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
138. Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez-MacGregor M., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
139. Gnant M. The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther 2009, 2:95-104.
140. Tanjore H., Zeisberg E.M., Gerami-Naini B., Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn 2008, 237:75-82.
141. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A 1997, 94:13612-13617.
142. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000, 97:2202-2207.
143. Kim S., Bell K., Mousa S.A., Varner J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000, 156:1345-1362.
144. Boudreau N.J., Varner J.A. The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. J Biol Chem 2004, 279:4862-4868.
145. Garmy-Susini B., Jin H., Zhu Y., Sung R.J., Hwang R., Varner J. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest 2005, 115:1542-1551.
146. Nikolopoulos S.N., Blaikie P., Yoshioka T., Guo W., Giancotti F.G. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 2004, 6:471-483.
147. Chung J., Bachelder R.E., Lipscomb E.A., Shaw L.M., Mercurio A.M. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002, 158:165-174.
148. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001, 98:12485-12490.
149. John A.S., Rothman V.L., Tuszynski G.P. Thrombospondin-1 (TSP-1) stimulates expression of integrin alpha6 in human breast carcinoma cells: a downstream modulator of TSP-1-induced cellular adhesion. J Oncol 2010, 2010:645376.
150. Eliceiri B.P., Cheresh D.A. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001, 13:563-568.
151. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
152. Brenner S., Whiting-Theobald N., Kawai T., Linton G.F., Rudikoff A.G., Choi U., et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells 2004, 22:1128-1133.
153. Kahn J., Byk T., Jansson-Sjostrand L., Petit I., Shivtiel S., Nagler A., et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004, 103:2942-2949.
154. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
155. Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol 2000, 37:11-18.
156. Hidalgo A., Peired A.J., Weiss L.A., Katayama Y., Frenette P.S. The integrin alphaMbeta2 anchors hematopoietic progenitors in the bone marrow during enforced mobilization. Blood 2004, 104:993-1001.
157. Stier S., Ko Y., Forkert R., Lutz C., Neuhaus T., Grunewald E., et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005, 201:1781-1791.
158. Christopher M.J., Liu F., Hilton M.J., Long F., Link D.C. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009, 114:1331-1339.
159. Adams G.B., Martin R.P., Alley I.R., Chabner K.T., Cohen K.S., Calvi L.M., et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007, 25:238-243.
160. Mendez-Ferrer S., Frenette P.S. Hematopoietic stem cell trafficking: regulated adhesion and attraction to bone marrow microenvironment. Ann N Y Acad Sci 2007, 1116:392-413.
161. Eash K.J., Means J.M., White D.W., Link D.C. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 2009, 113:4711-4719.
162. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
163. Bungartz G., Stiller S., Bauer M., Muller W., Schippers A., Wagner N., et al. Adult murine hematopoiesis can proceed without beta1 and beta7 integrins. Blood 2006, 108:1857-1864.
164. Jiang Y., Prosper F., Verfaillie C.M. Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors. Blood 2000, 95:846-854.
165. Voura E.B., Billia F., Iscove N.N., Hawley R.G. Expression mapping of adhesion receptor genes during differentiation of individual hematopoietic precursors. Exp Hematol 1997, 25:1172-1179.
166. Hemler M.E., Lobb R.R. The leukocyte beta 1 integrins. Curr Opin Hematol 1995, 2:61-67.
167. Coulombel L., Auffray I., Gaugler M.H., Rosemblatt M. Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 1997, 97:13-21.
168. Verfaillie C.M., McCarthy J.B., McGlave P.B. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 1991, 174:693-703.
169. Oostendorp R.A., Reisbach G., Spitzer E., Thalmeier K., Dienemann H., Mergenthaler H.G., et al. VLA-4 and VCAM-1 are the principal adhesion molecules involved in the interaction between blast colony-forming cells and bone marrow stromal cells. Br J Haematol 1995, 91:275-284.
170. Liesveld J.L., Winslow J.M., Frediani K.E., Ryan D.H., Abboud C.N. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 1993, 81:112-121.
171. Qian H., Tryggvason K., Jacobsen S.E., Ekblom M. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood 2006, 107:3503-3510.
172. Schreiber T.D., Steinl C., Essl M., Abele H., Geiger K., Muller C.A., et al. The integrin alpha9beta1 on hematopoietic stem and progenitor cells: involvement in cell adhesion, proliferation and differentiation. Haematologica 2009, 94:1493-1501.
173. Yin T., Li L. The stem cell niches in bone. J Clin Invest 2006, 116:1195-1201.
174. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
175. Chavakis E., Aicher A., Heeschen C., Sasaki K., Kaiser R., El Makhfi N., et al. Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med 2005, 201:63-72.
176. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
177. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
178. Pazolli E., Luo X., Brehm S., Carbery K., Chung J.J., Prior J.L., et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 2009, 69:1230-1239.
179. Wei S.C., Tsao P.N., Yu S.C., Shun C.T., Tsai-Wu J.J., Wu C.H., et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005, 54:666-672.
180. Marcellini M., De Luca N., Riccioni T., Ciucci A., Orecchia A., Lacal P.M., et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 2006, 169:643-654.
181. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
182. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
183. Sun Y.X., Fang M., Wang J., Cooper C.R., Pienta K.J., Taichman R.S. Expression and activation of alpha(v)beta(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67:61-73.
184. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003, 89:462-473.
185. Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Cook K., et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005, 20:318-329.
186. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
187. Parmo-Cabanas M., Bartolome R.A., Wright N., Hidalgo A., Drager A.M., Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004, 294:571-580.
188. Mahabeleshwar G.H., Feng W., Phillips D.R., Byzova T.V. Integrin signaling is critical for pathological angiogenesis. J Exp Med 2006, 203:2495-2507.
189. Feng W., McCabe N.P., Mahabeleshwar G.H., Somanath P.R., Phillips D.R., Byzova T.V. The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol 2008, 183:1145-1157.
190. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
191. Yang L., Edwards C.M., Mundy G.R. Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 2010, 25:1701-1706.
192. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
193. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006, 80:1183-1196.
194. Jin H., Su J., Garmy-Susini B., Kleeman J., Varner J. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res 2006, 66:2146-2152.
195. Hume D.A. The mononuclear phagocyte system. Curr Opin Immunol 2006, 18:49-53.
196. Sweet M.J., Hume D.A. CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp (Warsz) 2003, 51:169-177.
197. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267:204-215.
198. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
199. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
200. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
201. Chen Z.G., Bottazzi B., Wang J.M., Mantovani A. Tumor-associated macrophages in metastasizing tumors. Adv Exp Med Biol 1988, 233:61-71.
202. Chambers S.K., Kacinski B.M., Ivins C.M., Carcangiu M.L. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997, 3:999-1007.
203. Canioni D., Salles G., Mounier N., Brousse N., Keuppens M., Morchhauser F., et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008, 26:440-446.
204. Reyes-Reyes M., Mora N., Gonzalez G., Rosales C. beta1 and beta2 integrins activate different signalling pathways in monocytes. Biochem J 2002, 363:273-280.
205. Jin H., Aiyer A., Su J., Borgstrom P., Stupack D., Friedlander M., et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 2006, 116:652-662.
206. Sato T., Nakai T., Tamura N., Okamoto S., Matsuoka K., Sakuraba A., et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005, 54:1254-1262.
207. Schneider J.G., Zhu Y., Coleman T., Semenkovich C.F. Macrophage beta3 integrin suppresses hyperlipidemia-induced inflammation by modulating TNFalpha expression. Arterioscler Thromb Vasc Biol 2007, 27:2699-2706.
208. Savill J., Dransfield I., Hogg N., Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990, 343:170-173.
209. Savill J., Hogg N., Ren Y., Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992, 90:1513-1522.
210. Law D.A., DeGuzman F.R., Heiser P., Ministri-Madrid K., Killeen N., Phillips D.R. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999, 401:808-811.
211. Taverna D., Moher H., Crowley D., Borsig L., Varki A., Hynes R.O. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A 2004, 101:763-768.
212. Kanamori M., Kawaguchi T., Berger M.S., Pieper R.O. Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis. J Biol Chem 2006, 281:37256-37264.
213. Galarneau H., Villeneuve J., Gowing G., Julien J.P., Vallieres L. Increased glioma growth in mice depleted of macrophages. Cancer Res 2007, 67:8874-8881.
214. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007, 67:425. [author reply 426].
215. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007, 179:977-983.
216. Honn K.V., Tang D.G., Crissman J.D. Platelets and cancer metastasis: a causal relationship?. Cancer Metastasis Rev 1992, 11:325-351.
217. Billroth T. Pathology and therapeutics, in fifty lectures. Clin Orthop 1871, 2003:4-11.
218. Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol 2001, 106:33-42.
219. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725.
220. Phillips D.R., Charo I.F., Scarborough R.M. GPIIb-IIIa: the responsive integrin. Cell 1991, 65:359-362.
221. Smyth S.S., Reis E.D., Vaananen H., Zhang W., Coller B.S. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 2001, 98:1055-1062.
222. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999, 103:229-238.
223. Jurasz P., Stewart M.W., Radomski A., Khadour F., Duszyk M., Radomski M.W. Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol 2001, 134:1104-1112.
224. Karpatkin S. Role of thrombin in tumor angiogenesis, implantation, and metastasis. Pathophysiol Haemost Thromb 2003, 33(Suppl 1):54-55.
225. Nierodzik M.L., Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10:355-362.
226. Nierodzik M.L., Plotkin A., Kajumo F., Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991, 87:229-236.
227. Gasic G.J., Gasic T.B., Stewart C.C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968, 61:46-52.
228. Izumi Y., Taniuchi Y., Tsuji T., Smith C.W., Nakamori S., Fidler I.J., et al. Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: liver colonization and adhesion to vascular endothelial cells. Exp Cell Res 1995, 216:215-221.
229. Kim Y.J., Borsig L., Varki N.M., Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A 1998, 95:9325-9330.
230. Karpatkin S., Pearlstein E., Ambrogio C., Coller B.S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988, 81:1012-1019.
231. Lerner W.A., Pearlstein E., Ambrogio C., Karpatkin S. A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 1983, 31:463-469.
232. Nierodzik M.L., Bain R.M., Liu L.X., Shivji M., Takeshita K., Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol 1996, 92:452-457.
233. Mannori G., Crottet P., Cecconi O., Hanasaki K., Aruffo A., Nelson R.M., et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 1995, 55:4425-4431.
234. Bromberg M.E., Bailly M.A., Konigsberg W.H. Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb Haemost 2001, 86:1210-1214.
235. Camerer E., Qazi A.A., Duong D.N., Cornelissen I., Advincula R., Coughlin S.R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004, 104:397-401.
236. Francis J.L., Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002, 28:29-38.
237. Hu L., Lee M., Campbell W., Perez-Solar R., Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding and spontaneous metastasis. Blood 2004, 104:2746-2751.
238. Palumbo J.S., Talmage K.E., Massari J.V., La Jeunesse C.M., Flick M.J., Kombrinck K.W., et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005, 105:178-185.
239. Pearlstein E., Ambrogio C., Karpatkin S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res 1984, 44:3884-3887.
240. Rickles F.R., Patierno S., Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 2003, 124:58S-68S.
241. Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94:657-666.
242. Shi X., Gangadharan B., Brass L.F., Ruf W., Mueller B.M. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004, 2:395-402.
243. Amirkhosravi A., Amaya M., Siddiqui F.A. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999, 10:285-292.
244. Amirkhosravi A., Meyer T., Chang J.Y., Amaya M., Siddiqui F., Desai H., et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002, 87:930-936.
245. Rafii D.C., Psaila B., Butler J., Jin D.K., Lyden D. Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2008, 28:217-222.
246. Li X, Koh AJ, Wang Z, Soki FN, Park SI, Pienta KJ, et al. Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. J Bone Miner Res. 2010 [Epub ahead of print].
247. Beeton C.A., Bord S., Ireland D., Compston J.E. Osteoclast formation and bone resorption are inhibited by megakaryocytes. Bone 2006, 39:985-990.
248. Grundt A., Grafe I.A., Liegibel U., Sommer U., Nawroth P., Kasperk C. Direct effects of osteoprotegerin on human bone cell metabolism. Biochem Biophys Res Commun 2009, 389:550-555.
249. Chollet M.E., Brouland J.P., Bal dit Sollier C., Bauduer F., Drouet L., Bellucci S. Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br J Haematol 2010, 148:805-807.
250. Leven R.M., Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 1992, 20:1316-1322.
251. Schmitz B., Thiele J., Otto F., Farahmand P., Henze F., Frimpong S., et al. Evidence for integrin receptor involvement in megakaryocyte-fibroblast interaction: a possible pathomechanism for the evolution of myelofibrosis. J Cell Physiol 1998, 176:445-455.
252. Lemieux J.M., Horowitz M.C., Kacena M.A. Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation. J Cell Biochem 2010, 109:927-932.
253. Escudero N.D., Lacave M., Ubios A.M., Mandalunis P.M. Effect of monosodium olpadronate on osteoclasts and megakaryocytes: an in vivo study. J Musculoskelet Neuronal Interact 2009, 9:109-120.
254. Bernasconi S., Matteucci C., Sironi M., Conni M., Colotta F., Mosca M., et al. Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 1995, 60:300-307.
255. Zaslavsky A., Baek K.H., R.C.Lynch, Short S., Grillo J., Folkman J., et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010, 115:4605-4613.
256. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999, 222:124-138.
257. Khalili P., Arakelian A., Chen G., Plunkett M.L., Beck I., Parry G.C., et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006, 5:2271-2280.
258. Trikha M., De Clerck Y.A., Markland F.S. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res 1994, 54:4993-4998.
259. Ramos O.H., Kauskot A., Cominetti M.R., Bechyne I., Salla Pontes C.L., Chareyre F., et al. A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2008, 25:53-64.
260. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008, 8:604-617.
261. Fujii H., Komazawa H., Mori H., Kojima M., Itoh I., Murata J., et al. Antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogues and their inhibitory mechanisms. Biol Pharm Bull 1995, 18:1681-1688.
262. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822.
263. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008, 68:7711-7717.
264. Feng X., Novack D.V., Faccio R., Ory D.S., Aya K., Boyer M.I., et al. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 2001, 107:1137-1144.
265. Putz E., Witter K., Offner S., Stosiek P., Zippelius A., Johnson J., et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999, 59:241-248.
266. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001, 98:1853-1858.
267. Teti A., Migliaccio S., Baron R. The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?. Calcif Tissue Int 2002, 71:293-299.
268. Engelman V.W. A peptidomimetic antagonists of the avb3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997, 99:2284-2292.
269. Harms J.F., Welch D.R., Samant R.S., Shevde L.A., Miele M.E., Babu G.R., et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004, 21:119-128.
270. Nemeth J.A., Nakada M.T., Trikha M., Lang Z., Gordon M.S., Jayson G.C., et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007, 25:632-646.
271. Murphy M.G., Cerchio K., Stoch S.A., Gottesdiener K., Wu M., Recker R. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005, 90:2022-2028.
272. Smith J.W., Ruggeri Z.M., Kunicki T.J., Cheresh D.A. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990, 265:12267-12271.
273. Gramoun A., Shorey S., Bashutski J.D., Dixon S.J., Sims S.M., Heersche J.N., et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem 2007, 102:341-352.
274. Hariharan S., Gustafson D., Holden S., McConkey D., Davis D., Morrow M., et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007, 18:1400-1407.
275. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008, 27:86.
276. Legler D.F., Wiedle G., Ross F.P., Imhof B.A. Superactivation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci 2001, 114:1545-1553.
277. Alghisi G.C., Ponsonnet L., Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009, 4:e4449.
278. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
279. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone. 2010 [Epub ahead of print].
280. Bisanz K., Yu J., Edlund M., Spohn B., Hung M.C., Chung L.W., et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005, 12:634-643.
281. Danen E.H., Marcinkiewicz C., Cornelissen I.M., van Kraats A.A., Pachter J.A., Ruiter D.J., et al. The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells. Exp Cell Res 1998, 238:188-196.
282. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113:6206-6214.
283. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
284. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.S., Azab F., Leleu X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.